Surmounting the endothelial barrier for delivery of drugs and imaging tracers

Schnitzler, Johan G.; Dzobo, Kim E.; Nurmohamed, Nick S.; Stroes, Erik S.G.; Kroon, Jeffrey

doi:10.1016/j.atherosclerosis.2020.04.025

Cited by 4 publications

(3 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering activated endothelium in atheromatous plaque, available active targets may be centered on expressed adhesion molecules, receptors as well as impaired function, such as P selectins, ICAM 1, VCAM 1, αVβ3 integrin, and LOX-1 major receptors for LDL uptake by ECs, 14 biosynthesis of NO, MCP-1 secretion. Overexpressed P and E selectins, ICAM 1, VCAM 1 induced by inflammatory stimuli, mediating leukocytes adhering to lesional region, are the hallmark of atherosclerosis.…”

Section: Focusing On Several Pivotal Cellsmentioning

confidence: 99%

Recent advance in treatment of atherosclerosis: Key targets and plaque-positioned delivery strategies

Liu

Tan

et al. 2022

J Tissue Eng

View full text Add to dashboard Cite

Atherosclerosis, a chronic inflammatory disease of vascular wall, is a progressive pathophysiological process with lipids oxidation/depositing initiation and innate/adaptive immune responses. The coordination of multi systems covering oxidative stress, dysfunctional endothelium, diseased lipid uptake, cell apoptosis, thrombotic and pro-inflammatory responding as well as switched SMCs contributes to plaque growth. In this circumstance, inevitably, targeting these processes is considered to be effective for treating atherosclerosis. Arriving, retention and working of payload candidates mediated by targets in lesion direct ultimate therapeutic outcomes. Accumulating a series of scientific studies and clinical practice in the past decades, lesion homing delivery strategies including stent/balloon/nanoparticle-based transportation worked as the potent promotor to ensure a therapeutic effect. The objective of this review is to achieve a very brief summary about the effective therapeutic methods cooperating specifical targets and positioning-delivery strategies in atherosclerosis for better outcomes.

show abstract

Section: Focusing On Several Pivotal Cellsmentioning

confidence: 99%

Recent advance in treatment of atherosclerosis: Key targets and plaque-positioned delivery strategies

Liu

Tan

et al. 2022

J Tissue Eng

View full text Add to dashboard Cite

show abstract

“…In addition to direct exploitation of reconstituted HDL for treatment of disease, HDL-like nanoparticles are also explored for its utility to deliver drugs for treatment and tracers for imaging into the arterial wall or the brain or other tissues including cancers. The concept and state of the art of this strategy towards management of atherosclerosis is described extensively in another article of this review series [200]. Kratzer and colleagues demonstrated that proticle, nanoparticles made of protamines and oligonucleotides coated with apoA-I improve particle uptake and transcytosis through porcine brain capillary EC in vitro and that blocking SR-BI reduces transport to the level of uncoated proticles [201].…”

Section: Potential Relevance Of Transendothelial Hdl Transportmentioning

confidence: 99%

Transendothelial transport of lipoproteins

et al. 2020

View full text Add to dashboard Cite

The accumulation of low-density lipoproteins (LDL) in the arterial wall plays a pivotal role in the initiation and pathogenesis of atherosclerosis. Conversely, the removal of cholesterol from the intima by cholesterol efflux to high density lipoproteins (HDL) and subsequent reverse cholesterol transport shall confer protection against atherosclerosis. To reach the subendothelial space, both LDL and HDL must cross the intact endothelium. Traditionally, this transit is explained by passive filtration. This dogma has been challenged by the identification of several rate-limiting factors namely scavenger receptor SR-BI, activin like kinase 1, and caveolin-1 for LDL as well as SR-BI, ATP binding cassette transporter G1, and endothelial lipase for HDL. In addition, estradiol, vascular endothelial growth factor, interleukins 6 and 17, purinergic signals, and sphingosine-1-phosphate were found to regulate transendothelial transport of either LDL or HDL. Thorough understanding of transendothelial lipoprotein transport is expected to elucidate new therapeutic targets for the treatment or prevention of atherosclerotic cardiovascular disease and the development of strategies for the local delivery of drugs or diagnostic tracers into diseased tissues including atherosclerotic lesions.

show abstract

“…Targeted-imaging nanoparticles may also be used to specifically obtain information on the detail development and treatment of the specific lesions [11]. Recently, Schnitzler et al, [12] reported that the use of nanomedicines in drug delivery and tracer imaging improves the sensitivity and effectiveness of these agents intended for atherosclerotic diseases prevention by means of targeting the resident macrophages and activating the endothelial cells. Nanomedicines-based treatment has become an essential strategy for delivering safe and targeted nanoparticles to further reduce the residual risk of cardiovascular events [13].…”

Section: Introductionmentioning

confidence: 99%

Nanotechnology for Molecular Imaging of Atherosclerosis: Current Design and Approaches

Maslizan

Azmi

Jaafar

et al. 2021

ARFMTS

View full text Add to dashboard Cite

Atherosclerosis complications such as myocardial infarction or stroke is still one of the most critical causes of death worldwide. Advance and innovative diagnostic technologies are urgently required to discover an early stage of the disease, such as plaque instability and thrombosis. A combination of molecular imaging probes based on well-designed nanomaterials with leading-edge imaging methods is currently concreting the direction for novel and distinctive approaches to examine the inflammatory growth in atherosclerosis. Over the past several decades, an exceptional understanding of the biological nature of atherosclerosis provides unique opportunities to better treat atherosclerotic disease with targeted imaging and nanomedicines. Consequently, tremendous development has been initiated in the nanotechnology application; the leading engineering tools working at molecular range, which is designed for diagnostic and therapeutic approach, called theranostic. This review underlying ideas involving the potential and development of molecular imaging technologies that had been invented for studying atherosclerosis. We envisage that many molecular imaging methods will become valuable assistants to the clinical management of targeted treatment in the atherosclerosis disease together with their challenges and future perspective in clinical translation.

show abstract

Surmounting the endothelial barrier for delivery of drugs and imaging tracers

Cited by 4 publications

References 79 publications

Recent advance in treatment of atherosclerosis: Key targets and plaque-positioned delivery strategies

Recent advance in treatment of atherosclerosis: Key targets and plaque-positioned delivery strategies

Transendothelial transport of lipoproteins

Nanotechnology for Molecular Imaging of Atherosclerosis: Current Design and Approaches

Contact Info

Product

Resources

About